`Case 1:14—cv—O1453—LPS Document 62-1 Filed 12/23/15 Page 1 of 10 Page|D #: 1822
`
`EXHIBITA
`
`EXHIBIT A
`
`
`
`Asserted Fletemstfiireoiedtto Plhmmooeufioelwoducis and
`Case 1:14-cv-01453-LPS Document 62-1 Filed 12/23/15 Page 2 of 10 PageID #: 1823
`
`Formulations Useful to Prevent or Minimize Allergic Reactions
`
`
`
`-
`
`= E:I.it::I‘StItcs Patent
`
`" "'|""|H*-'|'Ijn1pu"
`i"tl'I"I-b u.u
`‘fl’;
`~-'I=-
`irl-tuna.-..;_....-\..__
`'L|.n-. u.
`._ 5
`
`-3
`
`-3'
`
`"n'="~n
`
`;|-.....«.| Ha,
`r
`I‘-H-‘H -- I-‘tr.-L-.'
`M :-t-.n-.
`-~-_....
`t=l"l.|-l.'|
`
`..
`
`H
`
`m:
`
`.._-_“I’“
`M-rah“
`
`. ..!.!!..““||
`
`'I:- Fllq-fl'lq.L
`_-~ n-mu-.....=
`
`_.£‘:f"fl',‘§
`
`The present my .
`and formulations.
`"
`"
`
`.
`
`»-
`
`_
`:r_:-L
`
`I
`
`,
`.:
`
`'___,
`:_-l‘-_
`
`I.
`
`_
`
`.
`._‘..I
`
`-.
`
`.
`
`.
`.
`.1.
`
`..
`
`-\_
`-_l
`
`_-
`.-
`._
`::.'r . I.
`
`I
`
`.
`'4.
`
`.
`
`I
`
`-
`.._,
`
`-
`
`,_-
`
`I.
`
`I
`
`-,
`._
`—
`..I .. 1-.
`
`-
`_.-!1-
`
`I
`
`an.
`.:.
`
`..
`
`.
`
`. ..
`_.
`E
`
`..
`1 I .
`
`.. .
`u
`‘
`
`.l
`
`|.h
`
`in :"‘""".'.'Z:‘
`" "
`
`'|
`
`-“.‘
`
`I-I-I.l"l.
`III-I! FF“
`
`I
`
`§§_i-’;
`
`-
`
`"-
`
`5I|Il‘|
`
`:1»-~=~
`
`‘
`
`t
`
`’
`
`.'.-...1:.‘-.. Moreparticu-
`:=.,'
`'~-‘.-‘:n.._'-.*.=-
`1".-":=;..'.'
`:.-='
`"I '.
`larly, but not exclusively, the present invention relates to
`pharmaceutical products and formulations for nasal and ocu-
`lar use.
`Such allergic reactions commonly comprise the allergy-
`related and vasomotor-related symptoms and the rhi11ovirus-
`related symptoms.
`
`3
`
`‘723 patent. Col l., II. 19-28.‘ "620 patent, COI 1., ll. lO~l9
`
`
`
`Case 1:14-cv-01453-LPS Document 62-1 Filed 12/23/15 Page 3 of 10 PageID #: 1824
`Case 1:14—cv—O1453—LPS Document 62-1 Filed 12/23/15 Page 3 of 10 Page|D #: 1824
`
`EXHIBITB
`
`EXHIBIT B
`
`
`
`Allergic Rfii1‘1iii§45li’§1[i‘i5“3”iE5i§"el5fi’ii3glil§'°Wii8E3lily of Life
`
`Case 1:14-cv-01453-LPS Document 62-1 Filed 12/23/15 Page 4 of 10 PageID #: 1825
`
`.r
`
`
`
`Prevalence of AR
`
`16.? million adults diognosed with AR In 201'!
`
`- Affects 2 of every IO odulls
`
`- Affects 4 of every IO children
`
`Impact on qucllily of life
`AR results in on esiimoied 3.8 million missed days of school and work each year
`
`- Couses signlficoni sleep irnpoirmenl. ossocioled cogniliveond
`
`psychiolric issues
`
`-
`
`In children: Sympioms of AR impolr cogniiive process ond reduced
`
`obilily to concenlrole in school
`
`-
`
`In odullsz Symptoms decreose workplace oroducliviiy, induces
`
`obsenleeisrn, reduction in produciivify ond increoses work impoirmenf
`
`References:
`
`- American College of Aslhmo. Allergy ond Immunology.
`hll
`: ~.w.rw.ocol.or
`oller
`isl news Po es filler
`Fools.
`fig
`- Schfller J5 Eli DI. Vital Heollh Biol. 2D'l2:lD[256].
`
`- Bloom B el ol, Vilol HE.-ollh Slol, 20l2:l0:[254|_
`~ Elousquei J elol. A.llergy.2008:63{suppl 851:8-léfl.
`- The Allergy Report, I-2.
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 62-1 Filed 12/23/15 Page 5 of 10 PageID #: 1826
`Case 1:14—cv—O1453—LPS Document 62-1 Filed 12/23/15 Page 5 of 10 Page|D #: 1826
`
`EXHIBITC
`
`EXHIBIT C
`
`
`
`Case 1:14-cv-01453-LPS Document 62-1 Filed 12/23/15 Page 6 of 10 PageID #: 1827
`
`I‘i‘i31E‘Eii”<i3tPSc$’iC1“mtFieF"iii’§i5 E96
`
`T
`
`Direct and indirect costs associated with AR
`
`In 2000, AR cost $6 billion in medical spending
`
`- By 2005, the costs associated with AR nearly doubled to $1 1.2 billion
`
`- An estimated 13.5 million physician visits annually
`
`- Lost productivity due to AR estimated at $1.000 per worker per year
`
`- Increased motor vehicle accidents
`
`- "Hidden“ costs due to AR leading to or complicating other high—cost
`
`disorders, such as asthma. sinusitis. otitis media, and nasal polyposis
`
`Reierences:
`
`- Sahatz. M. t200?]I, Asuweyat the burden of allergic rhinitis in the USA. Allergy, 62: 9-16. dai: till i
`9995.200?
`- Soni A. Statistical Brief #204. Bethesda. MD: Aaencv for Healthcare Research and Giuaity, 2008
`- The AI-erg-g Report. 1-2.
`
`'
`
`I l;‘].i398-
`
`
`
`Case 1:14-cv-01453-LPS Document 62-1 Filed 12/23/15 Page 7 of 10 PageID #: 1828
`Case 1:14—cv—O1453—LPS Document 62-1 Filed 12/23/15 Page 7 of 10 Page|D #: 1828
`
`EXHIBITD
`
`EXHIBIT D
`
`
`
`Claimezdollenvemfianwisza pcombinafion
`Case 1:14-cv-01453-LPS Document 62-1 Filed 12/23/15 Page 8 of 10 PageID #: 1829
`
`Pharmaceutical Product
`
`Combinofion of
`
`
`
`Azelastine ond Fluficasone
`
`in one dosoge form
`
`
`
`Case 1:14-cv-01453-LPS Document 62-1 Filed 12/23/15 Page 9 of 10 PageID #: 1830
`Case 1:14—cv—O1453—LPS Document 62-1 Filed 12/23/15 Page 9 of 10 Page|D #: 1830
`
`EXHIBITE
`
`EXHIBIT E
`
`
`
`Dymisia’?$eK4EW3?riE‘fir§‘3sF"‘5$§iagi5°r°i3? Products
`
`Case 1:14-cv-01453-LPS Document 62-1 Filed 12/23/15 Page 10 of 10 PageID #: 1831
`
`
`
`- Convenieni crll-in-one
`
`odminisiroiion
`
`- Improved relief of allergic
`rhinitis symptoms
`
`- Fcrsier onset of action
`
`25